Our mouse glioma model provides a unique entry point for studying the propensity of glioblastoma to amplify RTKs, as our model is genetically defined with only two initiating mutations–a point mutant of PDGFRα with elevated kinase activity and loss of INK4A/Arf. The gene discussed is CDKN2A; the disease is central nervous system cancer.